English
vaniprevir
Sign in to saveVaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
Wikidata facts
- Mass
- 757.372049
Show 4 more facts
- isomeric SMILES
- CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
- canonical SMILES
- CCC1CC1(C(=O)NS(=O)(=O)C2CC2)NC(=O)C3CC4CN3C(=O)C(NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
- chemical formula
- C₃₈H₅₅N₅O₉S
- Commons category
- Vaniprevir
Sources (2)
via Wikidata · CC0
~1 min read
Article
1 sectionsContents
- References
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
==References==
Connections
medication
Entity
influenza
Entity
digital object identifier
Entity
infection
Entity
chemical formula
Entity
hepatitis C
Entity
molar mass
Entity
Q180686
Entity
CAS Registry Number
Entity
interferon
Entity
PubChem
Entity
remdesivir
Entity
oseltamivir
Entity
RNA polymerase
Entity
clinical trial
Entity
antiviral drug
Entity
World Health Organization Model List of Essential Medicines
Entity
simplified molecular input line entry specification
Entity
RNA viruses
Entity
Merck & Co.
Company